References
- Cancer Research UK. Ovarian cancer incidence by stage at diagnosis. Cancer Statistics. 2017. [cited 2019 Nov 17]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer/incidence#heading-Three.
- Kitchener HC. Survival from cancer of the ovary in England and Wales up to 2001. Br J Cancer. 2008;99(S1):S73–S74. doi:https://doi.org/10.1038/sj.bjc.6604594.
- Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer. 2009;115(6):1234–1244. doi:https://doi.org/10.1002/cncr.24149.
- Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–257. doi:https://doi.org/10.1016/S0140-6736(14)62223-6.
- Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–953. doi:https://doi.org/10.1056/NEJMoa0908806.
- Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124(1):10–14. doi:https://doi.org/10.1016/j.ygyno.2011.08.014.
- McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39(2):210–213. doi:https://doi.org/10.1207/S15327914nc392_8.
- Bharadwaj S, Ginoya S, Tandon P, et al. Malnutrition: Laboratory markers vs nutritional assessment. Gastroenterol Rep. 2016;4(4):272–280. doi:https://doi.org/10.1093/gastro/gow013.
- Nazha B. Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate? World J Gastrointest Surg. 2015;7(12):370. doi:https://doi.org/10.4240/wjgs.v7.i12.370.
- Lai CC, You JF, Yeh CY, et al. Low preoperative serum albumin in colon cancer: A risk factor for poor outcome. Int J Colorectal Dis. 2011;26(4):473–481. doi:https://doi.org/10.1007/s00384-010-1113-4.
- Sirott MN, Bajorin DF, Wong GYC, et al. Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis. Cancer. 1993;72(10):3091–3098. doi:https://doi.org/10.1002/1097-0142(19931115)72:10 < 3091::AID-CNCR2820721034 > 3.0.CO;2-V.
- Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, et al. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012;87(11):1006–1009. doi:https://doi.org/10.1002/ajh.23303.
- Ayhan A, Günakan E, Alyazıcı İ, Haberal N, Altundağ Ö, Dursun P. The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer. Arch Gynecol Obstet. 2017;296(5):989–995. doi:https://doi.org/10.1007/s00404-017-4511-9.
- Wang X, Wang Y. The prognostic nutritional index is prognostic factor of gynecological cancer: A systematic review and meta-analysis. Int J Surg. 2019;67:79–86. doi:https://doi.org/10.1016/j.ijsu.2019.05.018.
- Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: A systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(9):1537–1549. doi:https://doi.org/10.1007/s00432-014-1714-3.
- Vergote I, Coens C, Nankivell M, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680–1687. doi:https://doi.org/10.1016/S1470-2045(18)30566-7.
- Marshall W. Albumin monograph. Association for Clinical Biochemistry. 2012. [cited 2019 Nov 17]. Available from: http://www.acb.org.uk/Nat.LabMedHbk/Albumin.pdf.
- Phillips A, Balega J, Nevin J, et al. Reporting ‘denominator’ data is essential for benchmarking and quality standards in ovarian cancer. Gynecol Oncol. 2017;146(1):94–100. doi:https://doi.org/10.1016/j.ygyno.2017.04.007.
- Oken MM, Creech RH, Davis TE. Toxicology and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol Cancer Clin Trials. 1982;5(6):649–656. doi:https://doi.org/10.1097/00000421-198212000-00014.
- Rustin GJS, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating recist 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–423. doi:https://doi.org/10.1097/IGC.0b013e3182070f17.
- Lee JL, Oh ES, Lee RW, Finucane TE. Serum albumin and prealbumin in calorically restricted, nondiseased individuals: A systematic review. Am J Med. 2015;128(9):1023–e1. doi:https://doi.org/10.1016/j.amjmed.2015.03.032.
- Al-Khafaji A, Webb AR. Should albumin be used to correct hypoalbuminemia in the critically ill? No. Transfus Alternat Transfus Med. 2003;5(4):392–396. doi:https://doi.org/10.1111/j.1778-428X.2003.tb00179.x.
- Moujaess E, Fakhoury M, Assi T, et al. The therapeutic use of human albumin in cancer patients’ management. Crit Rev Oncol Hematol. 2017;120:203–209. doi:https://doi.org/10.1016/j.critrevonc.2017.11.008.